



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GP/1645  
#11  
5-1-02  
R2.

Applicant: Thomas J. BRENNAN, et al

RECEIVED

Group Art Unit: 1645

Serial No.: 09/892,206

APR 24 2002

Customer No. 26619

Filed: June 26, 2001

TECH CENTER 1600/2900

Deposit Account #. 50-1271

Title: Transgenic Mice Containing Anaphylatoxin  
C3a Gene Disruptions

Docket/Order No. R-171

Date: October 24, 2001

PRELIMINARY AMENDMENT

RECEIVED

FEB 05 2002

Commissioner for Patents  
Washington, D.C. 20231

COPY OF PAPERS  
ORIGINALLY FILED

TECH CENTER 1600/2900

Dear Sir:

Prior to any action and/or consideration of the above-captioned application, please enter the following amendments.

In the Specification:

Please delete the paragraph at page 9, lines 16-19, and replace with the paragraph:

--Figure 2A-2B shows the design of the targeting construct used to disrupt anaphylatoxin C3a receptor genes. Figure 2A shows the anaphylatoxin C3a target gene sequence (SEQ ID NO:1), identifying the sequence to be deleted (SEQ ID NO:5) and its flanking sequences (SEQ ID NO:6 and SEQ ID NO:7). Figure 2B shows the sequences identified as SEQ ID NO:3 and SEQ ID NO:4, which were used as the targeting arms (homologous sequences) in the anaphylatoxin C3a receptor targeting construct.--

In the Drawings:

Please replace Figure 2A with new Figure 2A attached herewith.